DITROPAN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, France, Malta, Poland, South Africa, Spain, UK.

Active ingredients

The drug DITROPAN contains one active pharmaceutical ingredient (API):

1	Oxybutynin hydrochloride UNII L9F3D9RENQ - OXYBUTYNIN CHLORIDE
	Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.
	Read more about Oxybutinin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G04BD04	Oxybutynin	G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8039D
CA	Health Products and Food Branch	02243960, 02243961
ES	Centro de información online de medicamentos de la AEMPS	57185
FR	Base de données publique des médicaments	69224470
GB	Medicines & Healthcare Products Regulatory Agency	143229, 19922, 19940, 381290
MT	Medicines Authority	AA908/18101
PL	Rejestru Produktów Leczniczych	100019812, 100261163, 100284158, 100354893, 100379835
US	FDA, National Drug Code	50458-805, 50458-810
ZA	Health Products Regulatory Authority	L/5.4/104